

# Recombinant Human TNFSF13B/BAFF/CD257 Protein

Catalog No.: RP01730 **Recombinant**

## Sequence Information

Species	Gene ID	Swiss Prot
human	10673	Q9Y275

### Tags

N-6His

### Synonyms

DTL; BAFF; BLYS; CD257; TALL1; THANK;  
ZTNF4; TALL-1; TNLG7A;  
TNFSF20;TNFSF13B

## Product Information

Source	Purification
HEK293 cells	> 92% by SDS-PAGE.

### Endotoxin

&lt; 0.1EU/μg


### Formulation

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

## Contact

 | 400-999-6126 | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn) | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Background

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

## Basic Information

### Description

Recombinant human TNFSF13B/BAFF/CD257 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala134-Leu285) of human TNFSF13B/BAFF/CD257 (Accession #NP\_006564.1) fused with a 6×His tag at the N-terminus.

### Bio-Activity

Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μg/mL (100 μL/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.


### Storage

Store the lyophilized protein at -20°C to -80°C for 12 months.


After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.

# Validation Data



Recombinant human TNFSF13B/BAFF/CD257 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 19 kDa.



Immobilized Human TNFSF13B (Catalog: RP01730) at 5 µg/mL (100 µL/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.